Pomerantz Law Firm Initiates Class Action Against Insulet Corporation for Securities Violations

Class Action Lawsuit Filed Against Insulet Corporation

Pomerantz LLP has announced a class action lawsuit against Insulet Corporation (NASDAQ: PODD) and several of its officers. This legal action was filed in the United States District Court for the District of Massachusetts and is listed under the docket number 26-cv-13062. The lawsuit targets all individuals and entities, excluding the defendants, who purchased or acquired Insulet securities from February 21, 2025, to May 26, 2026. The lawsuit seeks to address alleged violations of federal securities laws and pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, along with Rule 10b-5.

Background of the Case

The complaint alleges that throughout the specified Class Period, Insulet's executives made materially false and misleading statements regarding the company’s operations, business, and compliance policies. Notably, the lawsuit contends that Insulet’s manufacturing controls and procedures were faulty, creating heightened risks of safety violations and potential injuries associated with its products. This information was allegedly not disclosed, leading to misinformation about the company’s true operational status.

Impact on Investors

Investors who acquired Insulet securities during the Class Period are encouraged to act swiftly, as they have until August 31, 2026, to request appointment as the Lead Plaintiff in this class action. Interested parties can find further details or discuss the action by reaching out to Danielle Peyton via email at [email protected] or by calling 646-581-9980. It is advisable to include a mailing address, phone number, and details of shares purchased in any inquiry.

Insulet Corporation Overview

Insulet is known for developing and manufacturing insulin delivery systems designed for individuals with insulin-dependent diabetes. Among their products, the Omnipod 5 automated insulin delivery system is significant. It features an integrated proprietary AID algorithm that works in conjunction with third-party continuous glucose monitors through Bluetooth communication. Additionally, Insulet's earlier model, the Omnipod Dash, also utilized similar technology but is now being phased out.

Recent Developments

The problems at Insulet started to come to light on March 12, 2026, when the company announced a voluntary Medical Device Correction for specific lots of Omnipod® 5 Pods after identifying manufacturing issues. This disclosure resulted in a significant drop in Insulet’s stock price, which plummeted by more than 6% the following day.
Then, on May 26, 2026, Insulet revealed another voluntary recall of various product lots, including the Omnipod® 5 and Omnipod Dash® systems, due to identified manufacturing issues that could lead to insufficient insulin delivery. This announcement caused the stock price to decline further.

About Pomerantz LLP

Pomerantz LLP, headquartered in New York, with additional offices in Chicago, Los Angeles, London, Paris, and Tel Aviv, is recognized as a leader in corporate, securities, and antitrust class litigation. Having been established by the late Abraham L. Pomerantz, known as a pioneer in the field of class actions, the firm has extensive experience advocating for victims of securities fraud and corporate misconduct. Over its long history, the firm has recovered billions for its clients.

For more information about joining the class action or to review the complaint, visit www.pomerantzlaw.com.